UA80561C2 - Substituted tetralins and indanes and use thereof - Google Patents
Substituted tetralins and indanes and use thereof Download PDFInfo
- Publication number
- UA80561C2 UA80561C2 UAA200503454A UA2005003454A UA80561C2 UA 80561 C2 UA80561 C2 UA 80561C2 UA A200503454 A UAA200503454 A UA A200503454A UA 2005003454 A UA2005003454 A UA 2005003454A UA 80561 C2 UA80561 C2 UA 80561C2
- Authority
- UA
- Ukraine
- Prior art keywords
- ylsulfanyl
- ureido
- item
- differs
- compound according
- Prior art date
Links
- 125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 title abstract 2
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 title 1
- 238000000034 method Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 32
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 16
- -1 phenyl-O- Chemical class 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 14
- 235000019260 propionic acid Nutrition 0.000 description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 229940125708 antidiabetic agent Drugs 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005256 alkoxyacyl group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/43—Y being a hetero atom
- C07C323/44—X or Y being nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42002602P | 2002-10-21 | 2002-10-21 | |
| US49578803P | 2003-08-15 | 2003-08-15 | |
| PCT/US2003/033371 WO2004037779A1 (en) | 2002-10-21 | 2003-10-17 | Substituted tetralins and indanes and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80561C2 true UA80561C2 (en) | 2007-10-10 |
Family
ID=32179777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200503454A UA80561C2 (en) | 2002-10-21 | 2003-10-17 | Substituted tetralins and indanes and use thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20040167211A1 (el) |
| EP (1) | EP1554240B1 (el) |
| JP (1) | JP4411275B2 (el) |
| KR (1) | KR100989394B1 (el) |
| CN (1) | CN100354259C (el) |
| AT (1) | ATE430728T1 (el) |
| AU (1) | AU2003279996B2 (el) |
| BR (1) | BR0315623A (el) |
| CA (1) | CA2502665A1 (el) |
| CY (1) | CY1110326T1 (el) |
| DE (1) | DE60327543D1 (el) |
| DK (1) | DK1554240T3 (el) |
| EA (1) | EA009554B1 (el) |
| ES (1) | ES2325783T3 (el) |
| HR (1) | HRP20050336B1 (el) |
| IL (1) | IL168147A (el) |
| ME (1) | MEP53108A (el) |
| MX (1) | MXPA05004192A (el) |
| NO (1) | NO332352B1 (el) |
| NZ (1) | NZ539451A (el) |
| PL (1) | PL376326A1 (el) |
| PT (1) | PT1554240E (el) |
| RS (1) | RS52079B (el) |
| SI (1) | SI1554240T1 (el) |
| TW (1) | TWI308563B (el) |
| UA (1) | UA80561C2 (el) |
| WO (1) | WO2004037779A1 (el) |
| ZA (1) | ZA200504064B (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060247314A1 (en) * | 2002-10-21 | 2006-11-02 | Xiaoli Chen | Substituted tetralins and indanes |
| EA009553B1 (ru) * | 2002-10-21 | 2008-02-28 | Янссен Фармацевтика Н.В. | Замещённые тетралины и инданы |
| WO2004037777A1 (en) * | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Treating syndrome x with substituted tetralins and indanes |
| US20060094786A1 (en) * | 2002-10-21 | 2006-05-04 | Xiaoli Chen | Treating syndrome X with substituted tetralins and indanes |
| AR048931A1 (es) * | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
| US7550467B2 (en) * | 2004-10-12 | 2009-06-23 | Schering Corporation | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| WO2014146995A1 (en) * | 2013-03-20 | 2014-09-25 | F. Hoffmann-La Roche Ag | Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU632809B2 (en) * | 1989-05-25 | 1993-01-14 | Takeda Chemical Industries Ltd. | Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof |
| GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
| AU7513494A (en) | 1993-08-06 | 1995-02-28 | Upjohn Company, The | 2-aminoindans as selective dopamine d3 ligands |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| WO1997047738A1 (fr) | 1996-06-13 | 1997-12-18 | Fujisawa Pharmaceutical Co., Ltd. | Acylase des lipopeptides cycliques |
| GB9822473D0 (en) | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| US6300339B1 (en) | 1998-10-21 | 2001-10-09 | Novo Nordisk A/S | Compounds, their preparation and use |
| TWI234557B (en) | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
| EP1259494A4 (en) * | 2000-02-18 | 2004-09-15 | Merck & Co Inc | ARYLOXY ACETIC ACIDS FOR DIABETES AND LIPID DISEASES |
| WO2002028821A2 (de) * | 2000-10-05 | 2002-04-11 | Bayer Aktiengesellschaft | Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften. |
| AU2002222549A1 (en) * | 2000-11-29 | 2002-06-11 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| JPWO2002046146A1 (ja) * | 2000-12-05 | 2004-04-08 | 杏林製薬株式会社 | 置換カルボン酸誘導体 |
| EP1345916A1 (en) * | 2000-12-20 | 2003-09-24 | Glaxo Group Limited | Substituted oxazoles and thiazoles as hppar alpha agonists |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| EP1372632A1 (en) | 2001-02-15 | 2004-01-02 | Pfizer Products Inc. | Proliferative activator receptor (ppar) compounds |
| BR0207285A (pt) | 2001-02-15 | 2004-02-10 | Pfizer Producs Inc | Agonistas de ppar |
| US6548538B2 (en) | 2001-05-22 | 2003-04-15 | Bayer Aktiengesellschaft | Propionic acid derivatives |
| UA82835C2 (en) * | 2001-12-03 | 2008-05-26 | Reddys Lab Ltd Dr | ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon |
| US20060094786A1 (en) * | 2002-10-21 | 2006-05-04 | Xiaoli Chen | Treating syndrome X with substituted tetralins and indanes |
| US20060247314A1 (en) * | 2002-10-21 | 2006-11-02 | Xiaoli Chen | Substituted tetralins and indanes |
| EA009553B1 (ru) * | 2002-10-21 | 2008-02-28 | Янссен Фармацевтика Н.В. | Замещённые тетралины и инданы |
| WO2004037777A1 (en) * | 2002-10-21 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Treating syndrome x with substituted tetralins and indanes |
| AR048931A1 (es) * | 2004-04-21 | 2006-06-14 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis |
-
2003
- 2003-10-17 EP EP03773302A patent/EP1554240B1/en not_active Expired - Lifetime
- 2003-10-17 AU AU2003279996A patent/AU2003279996B2/en not_active Ceased
- 2003-10-17 KR KR1020057006805A patent/KR100989394B1/ko active IP Right Grant
- 2003-10-17 US US10/688,379 patent/US20040167211A1/en not_active Abandoned
- 2003-10-17 BR BR0315623-0A patent/BR0315623A/pt not_active IP Right Cessation
- 2003-10-17 JP JP2005501641A patent/JP4411275B2/ja not_active Expired - Fee Related
- 2003-10-17 PL PL03376326A patent/PL376326A1/xx not_active Application Discontinuation
- 2003-10-17 SI SI200331635T patent/SI1554240T1/sl unknown
- 2003-10-17 ES ES03773302T patent/ES2325783T3/es not_active Expired - Lifetime
- 2003-10-17 AT AT03773302T patent/ATE430728T1/de active
- 2003-10-17 DE DE60327543T patent/DE60327543D1/de not_active Expired - Lifetime
- 2003-10-17 RS YU20050320A patent/RS52079B/sr unknown
- 2003-10-17 UA UAA200503454A patent/UA80561C2/uk unknown
- 2003-10-17 EA EA200500516A patent/EA009554B1/ru not_active IP Right Cessation
- 2003-10-17 MX MXPA05004192A patent/MXPA05004192A/es active IP Right Grant
- 2003-10-17 NZ NZ539451A patent/NZ539451A/en not_active IP Right Cessation
- 2003-10-17 WO PCT/US2003/033371 patent/WO2004037779A1/en active Application Filing
- 2003-10-17 CN CNB2003801060885A patent/CN100354259C/zh not_active Expired - Fee Related
- 2003-10-17 ME MEP-531/08A patent/MEP53108A/xx unknown
- 2003-10-17 PT PT03773302T patent/PT1554240E/pt unknown
- 2003-10-17 CA CA002502665A patent/CA2502665A1/en not_active Abandoned
- 2003-10-17 DK DK03773302T patent/DK1554240T3/da active
- 2003-10-21 TW TW092129193A patent/TWI308563B/zh not_active IP Right Cessation
-
2005
- 2005-04-14 HR HRP20050336AA patent/HRP20050336B1/hr not_active IP Right Cessation
- 2005-04-19 IL IL168147A patent/IL168147A/en unknown
- 2005-05-10 NO NO20052280A patent/NO332352B1/no not_active IP Right Cessation
- 2005-05-19 ZA ZA200504064A patent/ZA200504064B/en unknown
- 2005-06-03 US US11/145,119 patent/US7351857B2/en not_active Expired - Lifetime
-
2009
- 2009-08-04 CY CY20091100820T patent/CY1110326T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA80561C2 (en) | Substituted tetralins and indanes and use thereof | |
| US4940731A (en) | Method of treating premature ejaculation using sertraline | |
| CN101283955B (zh) | 氨基酸类高含量防腐水溶液 | |
| WO2002034705A3 (en) | C-nitroso compounds and use thereof | |
| RU2001121983A (ru) | Производные 2-амино-4H-3,1-бензоксазин-4-она для лечения ожирения | |
| WO2002038129A3 (en) | Delayed-release pharmaceutical formulations containing proinsulin c-peptide | |
| IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
| EP2161265A3 (en) | Compounds having selective inhibiting effect at GSK3 | |
| HUP0400382A2 (hu) | Késleltetett leadású készítmény és eljárás annak előállítására | |
| MY135954A (en) | Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid | |
| CN101495462B (zh) | 嘧啶衍生物及其作为杀虫剂的用途 | |
| FR2513117A1 (fr) | Agent contre la maladie de parkinson, comprenant de la threo-3, 4-dihydroxyphenylserine et un inhibiteur de decarboxylase | |
| JP2002541133A (ja) | 安息香酸エステルから誘導された化合物、該化合物を含有する組成物及びその使用 | |
| CN111588729A (zh) | β-烟酰胺单核苷酸在预防脱发或促进毛发生长产品中的应用 | |
| CA2577430A1 (en) | 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues as inhibitors of macrophage elastase | |
| RU2003116126A (ru) | Лактамные соединения и их фармацевтическое использование | |
| AR039163A1 (es) | Besilato de venlafaxina | |
| PT98758A (pt) | Processo para a preparacao de uma composicao sob a forma de comprimido ou drageia contendo um ingrediente activo de preferencia um derivado de aminoguanidina sensivel ao calor luz e humidade tendo estretura cristalina monoclinica | |
| RU98106625A (ru) | Производные колхицина и тиоколхицина, обладающие противовоспалительной и миорелаксирующей активностями | |
| KR950701905A (ko) | 치환된 (아릴알킬아미노벤질)아미노프로피온아미드 유도체, 이의 제조방법 및 간질치료제, 신경보호제 및 우울증치료제로서의 이의 용도(Substituted (arylalkyla-minobenzyl)aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents) | |
| SG82593A1 (en) | Antimicrobial composition and their use | |
| CH694420A5 (fr) | Collier anti-puces et anti-tiques pour chien et chat, à base de N-phénylpyrazole | |
| WO1991000088A1 (fr) | Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants | |
| CA1341268C (fr) | Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute | |
| KR980002023A (ko) | N-아세토닐벤즈아미드를 포함하는 살균 조성물 및 n-아세토닐벤즈아미드의 제조방법 |